B. Christensen

发表

Machine learning algorithms to estimate 10-Year survival in patients with bone metastases due to prostate cancer: toward a disease-specific survival estimation tool

J. Forsberg, R. Wedin, Yongmei Chen, 2022, BMC cancer.

IDENTIFY IMMUNE CELL TYPES AND BIOMARKERS ASSOCIATED WITH IMMUNE-RELATED ADVERSE EVENTS USING SINGLE CELL RNA SEQUENCING MICROSATELLITE INSTABILITY/MISMATCH REPAIR BIOMARKER TESTING DISPARITIES IN PATIENTS WITH ADVANCED COLORECTAL CANCER: IMPLICATIONS FOR IMMUNE CHECKPOINT INHIBITORS

Hanlee P. Ji, Lance T. Pflieger, S. Grimes, 2020 .

Diagnostic Accuracy of Ultrasound in Predicting Extrathyroidal Extension and Its Relation to Body Mass Index in a North American Population

E. Kandil, E. Toraih, Abdallah S. Attia, 2022, Biomedicines.

High-Dose Testosterone and Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer.

O. Sartor, P. Barata, J. Layton, 2019, Clinical genitourinary cancer.

Characterization of the tumor mutation burden in hepatobiliary tumors.

L. Nadauld, T. Rhodes, T. Barker, 2019, Journal of Clinical Oncology.

Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell Carcinoma

P. Barata, V. Koshkin, Yasmin Hajja, 2021, Current Treatment Options in Oncology.

Neuroendocrine Carcinoma as a Cause of Humoral Hypercalcemia of Malignancy: A Case of a Patient With Elevated Parathyroid Hormone-Related Protein

M. Rendo, B. Christensen, J. Fenderson, 2022, Cureus.

TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer.

O. Sartor, P. Barata, J. Layton, 2019, Clinical genitourinary cancer.

Cosegregation of cfDNA AR amplifications and mutations in relation to BRAF and MYC in CRPC.

J. Layton, Elisa M Ledet, B. Christensen, 2018 .